MX2011003117A - Conjugados polimericos de peptidos terapeuticos. - Google Patents

Conjugados polimericos de peptidos terapeuticos.

Info

Publication number
MX2011003117A
MX2011003117A MX2011003117A MX2011003117A MX2011003117A MX 2011003117 A MX2011003117 A MX 2011003117A MX 2011003117 A MX2011003117 A MX 2011003117A MX 2011003117 A MX2011003117 A MX 2011003117A MX 2011003117 A MX2011003117 A MX 2011003117A
Authority
MX
Mexico
Prior art keywords
peptide
conjugate
mpeg
therapeutic
therapeutic peptide
Prior art date
Application number
MX2011003117A
Other languages
English (en)
Spanish (es)
Inventor
Mary J Bossard
Ping Zhang
Harold Zappe
C Simone Jude-Fishburn
Steven O Roczniak
Yujun Wang
Dawei Sheng
Elizabeth Minamitani
Xiaofeng Liu
Haim Moskowitz
Dennis Fry
Cherie Ali
Christine Taylor Brew
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2011003117A publication Critical patent/MX2011003117A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2011003117A 2008-09-19 2009-09-17 Conjugados polimericos de peptidos terapeuticos. MX2011003117A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19267208P 2008-09-19 2008-09-19
US20808909P 2009-02-18 2009-02-18
US15396609P 2009-02-19 2009-02-19
PCT/US2009/005192 WO2010033207A1 (en) 2008-09-19 2009-09-17 Polymer conjugates of therapeutic peptides

Publications (1)

Publication Number Publication Date
MX2011003117A true MX2011003117A (es) 2011-04-21

Family

ID=41226622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011003117A MX2011003117A (es) 2008-09-19 2009-09-17 Conjugados polimericos de peptidos terapeuticos.

Country Status (7)

Country Link
US (5) US20110166063A1 (enExample)
EP (3) EP2898900B1 (enExample)
JP (2) JP5765813B2 (enExample)
AU (1) AU2009292643B2 (enExample)
CA (1) CA2737040C (enExample)
MX (1) MX2011003117A (enExample)
WO (2) WO2010033207A1 (enExample)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
JP5564249B2 (ja) 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
US20110171166A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
EP2334337A1 (en) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US20110171162A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
WO2010033216A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
WO2010033222A2 (en) * 2008-09-19 2010-03-25 Netkar Therapeutics Polymer conjugates of ziconotide peptides
EP2337585A1 (en) * 2008-09-19 2011-06-29 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
WO2010033205A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of v681-like peptides
EP2340047A1 (en) * 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of kiss1 peptides
EP2340045B1 (en) 2008-09-19 2017-04-12 Nektar Therapeutics Polymer conjugates of protegrin peptides
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
AU2009321508B2 (en) 2008-11-03 2015-03-12 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US8916693B2 (en) 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
EP2553019A1 (en) 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
NZ603399A (en) * 2010-05-17 2014-09-26 Cebix Inc Pegylated c-peptide
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
KR102591732B1 (ko) * 2010-11-12 2023-10-19 넥타르 테라퓨틱스 Il-2 부분 및 중합체의 접합체
CA2824471C (en) 2011-01-04 2020-07-21 Bender Analytical Holding B.V. Cross-linked polymers and implants derived from electrophilically activated polyoxazoline
CN106146664B (zh) 2011-03-31 2021-09-07 Adc治疗股份有限公司 针对肾相关抗原1的抗体及其抗原结合片段
EP2714070B1 (en) * 2011-06-02 2024-03-20 OPKO Biologics Ltd. Long-acting glp-1/glucagon receptor agonists
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
UA126465C2 (uk) 2011-06-10 2022-10-12 Ханмі Сайенс Ко., Лтд. Пептид, що має активність оксинтомодуліну, та фармацевтична композиція для лікування ожиріння, яка його містить
PL2721062T3 (pl) 2011-06-17 2019-05-31 Hanmi Science Co Ltd Koniugat zawierający oksyntomodulinę oraz fragment immunoglobuliny i jego zastosowanie
US9127038B2 (en) 2011-08-04 2015-09-08 Merck Sharp & Dohme Corp. Kisspeptide-pentasaccharide conjugates
WO2013020914A1 (en) * 2011-08-10 2013-02-14 Celares Gmbh Peg-conjugated peptides
EP2741781A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
EP2768518A4 (en) * 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
EP2783388A4 (en) 2011-11-23 2015-12-09 Quest Diagnostics Invest Inc DETECTION OF KISSPEPTIN-54 BY TANDEM MASS SPECTROMETRY
JP6159973B2 (ja) 2012-01-02 2017-07-12 ユニヴェルシテイト ヘントUniversiteit Gent ポリオキサゾリンポリマー及びそれらの製造方法、これらのポリマーのコンジュゲート並びにそれらの医学的使用
CA3115623A1 (en) 2012-01-09 2013-07-18 Adc Therapeutics Sa Method for treating breast cancer
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
ES2425448B8 (es) * 2012-03-12 2015-03-17 Universidade De Santiago De Compostela Uso de la obestatina para la regeneración muscular
JP6178399B2 (ja) 2012-03-16 2017-08-09 ベンデル アナリティカル ホールディング ビー.ブイ.Bender Analytical Holding B.V. 求核的に活性化したポリオキサゾリンに由来する架橋ポリマー及び医療製品
US9522945B2 (en) 2012-04-19 2016-12-20 Opko Biologics Ltd. Long-acting oxyntomodulin variants and methods of producing same
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
JP5990324B2 (ja) * 2012-05-21 2016-09-14 エーティーファーマ シーオー.,エルティディ. 生理活性ペプチド複合体
PE20150181A1 (es) * 2012-06-04 2015-02-28 Opko Biolog Ltd Variantes de oxm pegilada
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
PT2916819T (pt) 2012-11-06 2019-10-28 Hanmi Pharm Ind Co Ltd Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina.
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
SG10202010383YA (en) 2012-11-20 2020-11-27 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US9919059B2 (en) * 2012-12-10 2018-03-20 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
SI24318A (sl) * 2013-03-13 2014-09-30 Diagen D.O.O. Nove stabilne soli pentadekapeptida, postopek za njihovo pripravo, njihova uporaba za izdelavo farmacevtskih pripravkov in njihova uporaba v terapiji
US20160039877A1 (en) * 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
US20150050213A1 (en) * 2013-08-14 2015-02-19 University Of Virginia Patent Foundation Compositions and methods for imaging inflammation of traumatic brain injury
WO2015048072A2 (en) * 2013-09-24 2015-04-02 Board Of Regents, The University Of Texas System Mucin-associated surface protein as vaccine against chagas disease
US10279023B2 (en) 2013-09-24 2019-05-07 Board Of Regents, The University Of Texas System Mucin-associated surface protein as a vaccine against chagas disease
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
WO2016004048A2 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
WO2016019340A1 (en) * 2014-07-31 2016-02-04 Serina Therapeutics, Inc. Polyoxazoline antibody drug conjugates
WO2016023036A1 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California High density peptide polymers
EP3185881B1 (en) * 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015328825B2 (en) 2014-10-06 2019-02-21 Gatt Technologies B.V. Tissue-adhesive porous haemostatic product
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
EA201791275A1 (ru) 2014-12-10 2017-12-29 Опко Байолоджикс Лтд. Способы получения ctp-модифицированных полипептидов длительного действия
CN105777892A (zh) * 2014-12-17 2016-07-20 深圳翰宇药业股份有限公司 普兰林肽聚乙二醇衍生物、其制备方法及其应用
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその使用
IL301728A (en) 2015-06-19 2023-05-01 Opko Biologics Ltd Long-term coagulation factors and methods for their preparation
EP3355903A1 (en) 2015-10-02 2018-08-08 University of Copenhagen Small molecules blocking histone reader domains
MA47290A (fr) 2015-10-08 2019-11-27 Nektar Therapeutics Combinaison d'un agoniste sélectif de l'il-2rbeta et d'un agoniste de l'il-15 à action prolongée
KR101642962B1 (ko) 2015-11-05 2016-07-26 (주)제이월드 봉합사 및 그 제조 방법
RU2605385C2 (ru) * 2015-11-23 2016-12-20 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения моноконъюгата полисиаловой кислоты с тимозином бета 4 и ковалентный моноконъюгат полисиаловой кислоты с тимозином бета 4, устойчивый к деградации в токе крови
RU2607527C2 (ru) * 2015-11-23 2017-01-10 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Ковалентный моноконъюгат полиэтиленгликоля с тимозином бета 4, устойчивый к деградации в токе крови, и способ его получения
BR112018016774A2 (pt) 2016-02-16 2018-12-26 Strongbridge Ireland Limited veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
HUE064463T2 (hu) 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások
US20180078342A1 (en) * 2016-09-21 2018-03-22 William Graham Gardner Dental Appliance For Use as an Aligner and as a Tool to Reduce Temporomandibular Dysfunction
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
CN111093688B (zh) * 2017-05-15 2025-09-16 尼克塔治疗公司 长效白细胞介素-15受体激动剂以及相关免疫治疗组合物和方法
CN109206481B (zh) * 2017-07-05 2023-08-18 尚华医药科技(江西)有限公司 一种肽类化合物、其应用及含其的组合物
JP7137625B2 (ja) * 2017-12-29 2022-09-14 エフ.ホフマン-ラ ロシュ アーゲー Peg化タンパク質組成物を提供するための方法
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
WO2021030326A1 (en) * 2019-08-12 2021-02-18 Northwestern University Brush polymers for therapeutic applications
US12516145B2 (en) 2019-09-30 2026-01-06 Northwestern University Bioactive peptide brush polymers via photoinduced reversible-deactivation radical polymerization
US20210106649A1 (en) * 2019-10-11 2021-04-15 TOBEBIO Novel Drug Laboratory Co., Ltd. Synergistic combination of chemotherapy and peptide for treating cancer
EP4072592A4 (en) * 2019-12-03 2024-06-12 Indian Institute of Technology, Delhi A process for preparation of pegylated therapeutic proteins
JP2023510089A (ja) * 2019-12-13 2023-03-13 フォリウムラボ インコーポレーティッド 炭水化物ポリマー及び活性成分を備える錯体及びそれらを調製する方法
CN111494318B (zh) * 2020-04-28 2022-04-12 华中科技大学同济医学院附属协和医院 一种肿瘤靶向和还原敏感型复合胶束及其制备方法和应用
WO2022035947A1 (en) * 2020-08-12 2022-02-17 Wisconsin Alumni Research Foundation Conjugation of proteins to polysaccharides using a phosphate bridge
KR20220076375A (ko) * 2020-11-30 2022-06-08 세종대학교산학협력단 신규 퇴행성 신경질환 치료용 약학적 조성물
BR112023016627A2 (pt) * 2021-03-08 2023-09-26 Akershus Univ Hf Ensaio de depuração
CN113134075B (zh) * 2021-04-29 2024-05-10 江苏普莱医药生物技术有限公司 一种抗菌肽乳膏及其制备方法
US20240408215A1 (en) 2021-09-08 2024-12-12 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Use of diazirine linker for drug conjugates
CN114395597B (zh) * 2021-12-17 2024-04-09 佛山汉腾生物科技有限公司 Glp-1或其变体的羟基化检测方法
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
CN116036234B (zh) * 2023-01-17 2024-02-06 青岛市中心医院 一种用于治疗骨质疏松的药剂
WO2024249889A1 (en) * 2023-05-31 2024-12-05 University Of Connecticut Genetic sequence/small molecule-carbohydrate conjugates for enhanced lung-specific targeting
CN118666949B (zh) * 2024-06-27 2025-07-29 首都医科大学 熊果酰-Arg-Gly-Asp-Ser的四聚体,其合成,活性和应用
CN118440155B (zh) * 2024-07-11 2024-11-22 中国药科大学 一种双激动多肽化合物及其医药用途

Family Cites Families (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2224175B1 (enExample) 1973-04-04 1978-04-14 Isf Spa
IT1017153B (it) * 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
US4010148A (en) * 1975-05-12 1977-03-01 Board Of Regents Of The University Of Texas System Purified thymosin and process
US4148788A (en) * 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
US4247066A (en) * 1978-02-21 1981-01-27 General Dynamics Corporation Airfoil variable cambering device and method
US4321260A (en) * 1980-05-22 1982-03-23 Ayerst, Mckenna & Harrison Inc. Method of using gonadorelin for the treatment of benign prostatic hyperplasia
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
SE438261B (sv) * 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
CH650679A5 (de) 1981-08-27 1985-08-15 Lilly Co Eli Gegen diabetes mellitus wirksames pharmazeutisches mittel.
US4652548A (en) * 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
EP0076676B1 (en) 1981-10-05 1986-12-30 Tni Pharmaceuticals, Inc. Process for using endorphins as antitumour agents
US4461724A (en) 1981-10-28 1984-07-24 Nippon Zoki Pharmaceutical Co., Ltd. Peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them
GB8314308D0 (en) 1983-05-24 1983-06-29 Matburn Holdings Ltd Medical administration devices
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4585754A (en) * 1984-01-09 1986-04-29 Valcor Scientific, Ltd. Stabilization of proteins and peptides by chemical binding with chondroitin
US5028703A (en) 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4805811A (en) * 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
US4668281A (en) * 1985-05-20 1987-05-26 E. I. Du Pont De Nemours And Company Thiophenesulfonamides
US5256549A (en) 1986-03-28 1993-10-26 Chiron Corporation Purification of synthetic oligomers
US4801612A (en) 1986-07-03 1989-01-31 Regents Of The University Of California Method of inhibiting inflammatory response
DE3634952A1 (de) * 1986-10-14 1988-04-21 Bayer Ag Imidazo-pyrrolo-pyridin-derivate
AT387234B (de) 1987-03-05 1988-12-27 Vogelbusch Gmbh Vorrichtung zur zuechtung von dauerformen insbesondere filamentoeser mikroorganismen
US4966753A (en) 1987-08-18 1990-10-30 Molecular Rx, Inc. Immunotherapeutic methods and compositions employing antigens characteristic of malignant neoplasms
US5468481A (en) 1988-06-23 1995-11-21 Amergen, Inc. MHC class II-peptide conjugates useful in ameliorating autoimmunity
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5049656A (en) * 1988-12-21 1991-09-17 Board Of Regents Of The University Of Nebraska Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
GB8909891D0 (en) 1989-04-28 1989-06-14 Riker Laboratories Inc Device
EP0400472B1 (en) * 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
US5137871A (en) 1989-07-28 1992-08-11 Regents Of The University Of California Treatment to reduce edema for brain and musculature injuries
YU176089A (sh) * 1989-09-12 1992-09-07 Sikirić, Predrag Postupak za pripremu supstancije bpc i supstancija bpc
GB8921222D0 (en) 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5545719A (en) * 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
US5888762A (en) * 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
DE69132407T2 (de) 1990-06-28 2001-04-05 Glaxo Wellcome Inc., Research Triangle Park Aerosol arzneiformulierungen
IT1243344B (it) 1990-07-16 1994-06-10 Promo Pack Sa Inalatore plurimonodose per medicamenti in polvere
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ES2117045T3 (es) * 1990-12-21 1998-08-01 Curative Tech Inc Peptidos angiogenicos.
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
CA2103577A1 (en) 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5320094A (en) * 1992-01-10 1994-06-14 The Johns Hopkins University Method of administering insulin
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
DE4216133A1 (de) 1992-05-15 1993-11-18 Bissendorf Peptide Gmbh Anwendung von Urodilatin bei Lungen- und Bronchialerkrankungen
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) * 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5817628A (en) 1992-12-02 1998-10-06 The Rockefeller University Dynorphin a suppression of natural killer cell activity
US5470949A (en) * 1992-12-15 1995-11-28 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for making amino acid glycosides and glycopeptides
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5492688A (en) * 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US6653442B1 (en) 1993-07-20 2003-11-25 Intrabiotics Pharmaceuticals, Inc. Protegrins
US5804558A (en) 1993-07-20 1998-09-08 University Of California Protegrins
IS1736B (is) 1993-10-01 1999-12-30 Astra Ab Aðferð og tæki sem stuðla að aukinni samloðun agna
IT1271486B (it) 1993-10-12 1997-05-28 Italfarmaco Spa Oligopeptidi immunomodulatori derivati di frammenti della proteina c- reattiva
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5388572A (en) * 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5457044A (en) 1993-10-29 1995-10-10 Genentech, Inc. Method for collection of aerosolized proteins by inert filtration
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
PT735884E (pt) 1993-12-20 2000-09-29 Minnesota Mining & Mfg Formulacoes de aerossol de flunisolida
ES2218543T3 (es) 1994-03-07 2004-11-16 Nektar Therapeutics Procedimiento y preparacion para la administracion de insulina por via pulmonar.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5629384A (en) * 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5522385A (en) * 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6379670B1 (en) * 1994-11-18 2002-04-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US6014970A (en) * 1998-06-11 2000-01-18 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US6205999B1 (en) * 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6085740A (en) * 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
KR19980703876A (ko) 1995-04-14 1998-12-05 스티븐 엘. 허스트 분산성이 개선된 분말화된 약학적 조성물
US5692095A (en) 1995-05-10 1997-11-25 Allports, Inc. Capillary feed boiler
US6162046A (en) * 1995-05-10 2000-12-19 Allports Llc International Liquid vaporization and pressurization apparatus and methods
US6585509B2 (en) * 1995-05-10 2003-07-01 Allports Llc International Vaporization and pressurization of liquid in a porous material
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
PL185040B1 (pl) 1995-06-07 2003-02-28 Affymax Tech Nv Peptyd wiążący się z receptorami erytropoetyny, kompozycja farmaceutyczna zawierająca ten peptyd i jego zastosowanie do wytwarzania środka leczniczego
US5795864A (en) 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US5929237A (en) 1995-10-27 1999-07-27 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5610136A (en) * 1996-01-30 1997-03-11 Milkhaus Laboratory, Inc. Method for treatment of benign prostatic hypertrophy
US5826633A (en) 1996-04-26 1998-10-27 Inhale Therapeutic Systems Powder filling systems, apparatus and methods
DE19628705A1 (de) * 1996-07-08 1998-01-15 Fresenius Ag Neue Sauerstoff-Transport-Mittel, diese enthaltende Hämoglobin-Hydroxyethylstärke-Konjugate, Verfahren zu deren Herstellung, sowie deren Verwendung als Blutersatzstoffe
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
AU5806998A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
NZ502993A (en) 1997-09-08 2002-12-20 Metabolic Pharm Ltd Treatment of obesity using hGH 177-191analogues
DE69813853T3 (de) 1997-09-29 2011-05-12 Novartis Ag Perforierte mikroteilchen und deren verwendung
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6362254B2 (en) * 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
JP2002510603A (ja) * 1998-04-08 2002-04-09 イーライ・リリー・アンド・カンパニー ラロキシフェンの肺および鼻腔デリバリー
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
US6257233B1 (en) * 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
AU4729199A (en) * 1998-06-29 2000-01-17 Center For Blood Research, Inc., The Monocyte locomotion inhibitory factor
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
DE19835346A1 (de) 1998-08-05 2000-02-10 Boehringer Ingelheim Pharma Zweiteilige Kapsel zur Aufnahme von pharmazeutischen Zubereitungen für Pulverinhalatoren
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規g蛋白質共役型レセプター蛋白質、そのdnaおよびそのリガンド
ATE419273T1 (de) 1998-11-13 2009-01-15 Cyclacel Ltd Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
DE60024992T2 (de) 1999-04-23 2006-08-24 Battelle Memorial Institute, Columbus Richtungsverstellbarer ehd- aerosol-zerstäuber
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
SE9902627D0 (sv) 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
US6323311B1 (en) 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
MXPA02003176A (es) * 1999-10-04 2002-09-30 Shearwater Corp Neuropeptidos estabilizados por polimero.
DE19951471A1 (de) 1999-10-26 2001-05-03 Forssmann Wolf Georg Verwendung von Urodilatin zur Behandlung chronischer Niereninsuffizienz mit Nierenrestfunktionen
MXPA02004193A (es) * 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
AUPQ387599A0 (en) 1999-11-05 1999-12-02 Metabolic Pharmaceuticals Limited Product and method for control of obesity
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
WO2001044469A1 (fr) 1999-12-17 2001-06-21 Takeda Chemical Industries, Ltd. PROCEDE DE PRODUCTION DE PEPTIDE KiSS-1
PT1259563E (pt) * 1999-12-22 2009-04-14 Nektar Therapeutics Al Corp Processo para a preparação de ésteres de 1-benzotriazolil- -carbonato de polímeros solúveis em água
DE60026073T2 (de) 1999-12-22 2006-09-28 Nektar Therapeutics Al, Corp., Huntsville Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
CA2404257A1 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Novel protein, dna thereof and process for producing the same
US6884778B2 (en) * 2000-04-14 2005-04-26 William Marsh Rice University Biocompatible macromers
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
EP1297839A4 (en) * 2000-06-23 2005-12-07 Kaken Pharma Co Ltd PREVENTIVA OR THERAPEUTIC AGAINST HEART FAILURE
US6357490B1 (en) * 2000-08-22 2002-03-19 Advanced Inhalation Research, Inc. System, method and apparatus for filling containers
WO2002022151A2 (en) 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
US20020065397A1 (en) * 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
AU2000202A (en) * 2000-10-31 2002-05-15 Pr Pharmaceuticals Inc Methods and compositions for enhanced delivery of bioactive molecules
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
WO2002085399A1 (fr) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
US6803565B2 (en) 2001-05-18 2004-10-12 Battelle Memorial Institute Ionization source utilizing a multi-capillary inlet and method of operation
US6583408B2 (en) * 2001-05-18 2003-06-24 Battelle Memorial Institute Ionization source utilizing a jet disturber in combination with an ion funnel and method of operation
CA2447236A1 (en) * 2001-05-21 2002-11-28 Nektar Therapeutics Pulmonary administration of chemically modified insulin
US7766013B2 (en) * 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
ATE360034T1 (de) 2001-09-19 2007-05-15 Takeda Pharmaceutical Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
UA78726C2 (en) 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
MXPA04004336A (es) * 2001-11-07 2005-05-16 Nektar Therapeutics Al Corp Polimeros ramificados y sus conjugados.
JP2005509888A (ja) 2001-11-16 2005-04-14 ウオーターズ・インベストメンツ・リミテツド Maldiターゲット上への濃縮、脱塩および被着の並列処理
US6701922B2 (en) * 2001-12-20 2004-03-09 Chrysalis Technologies Incorporated Mouthpiece entrainment airflow control for aerosol generators
US7458373B2 (en) 2002-01-15 2008-12-02 Philip Morris Usa Inc. Aerosol generator for drug formulation
AU2003213152A1 (en) 2002-02-15 2003-09-09 Nektar Therapeutics Al, Corporation Hydrolytically degradable alkylene oxide based polymers
US6634864B1 (en) 2002-02-19 2003-10-21 Vapore, Inc. High fluid flow and pressure in a capillary pump for vaporization of liquid
PL205811B1 (pl) 2002-08-13 2010-05-31 Iwona Bonney Zastosowanie peptydów o działaniu analgetycznym jako substancji czynnej w urządzeniach do podawania leku bezpośrednio do miejsca ich spodziewanego działania przeciwbólowego
KR100974843B1 (ko) * 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
MXPA05002594A (es) * 2002-09-11 2005-05-27 Fresenius Kabi Gmbh Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
DK2261249T3 (en) 2002-09-12 2015-02-16 Oncotherapy Science Inc KDR peptides and vaccines comprising the same
BR0316560A (pt) * 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
US7648962B2 (en) * 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
AU2003303636B2 (en) 2002-12-26 2010-08-05 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
CN102319437B (zh) 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
US6800611B2 (en) 2003-01-06 2004-10-05 Takeda Chemical Industries, Ltd. Metastin derivatives and their use
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
WO2004085471A2 (en) * 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
BRPI0409322B8 (pt) 2003-04-11 2021-05-25 Antriabio Inc método para preparar um conjugado de insulina-polímero
KR20060013515A (ko) 2003-04-23 2006-02-10 사이클론 파아머슈티컬 인코오퍼레이티드 알파 티모신 펩티드에 의한 호흡기 바이러스 감염 치료또는 예방
ES2725808T3 (es) * 2003-05-23 2019-09-27 Nektar Therapeutics Derivados de PEG que contienen dos cadenas de PEG
US20050074425A1 (en) * 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
WO2005014024A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of a polymer and a protein linked by an oxime linking group
JP2007501888A (ja) 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
CN1852740B (zh) 2003-09-17 2011-05-11 耐科塔医药公司 多支链聚合物的药物前体
WO2005032556A1 (en) 2003-10-02 2005-04-14 Elan Pharmaceuticals, Inc. Method for reducing pain
JP2007521453A (ja) 2003-10-21 2007-08-02 ヴェイポア インコーポレイテッド 液体気化用キャピラリポンプ
WO2005047337A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
WO2005099768A2 (en) 2004-03-23 2005-10-27 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
JP2007530697A (ja) 2004-03-29 2007-11-01 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ 両親媒性グリコペプチド
US7290541B2 (en) 2004-04-20 2007-11-06 Aerogen, Inc. Aerosol delivery apparatus and method for pressure-assisted breathing systems
US7946291B2 (en) 2004-04-20 2011-05-24 Novartis Ag Ventilation systems and methods employing aerosol generators
CA2562676A1 (en) 2004-04-23 2005-12-15 Applied Research Systems Ars Holding N.V. Use of gpcr54 ligands for the treatment of infertility
CN100355786C (zh) 2004-04-28 2007-12-19 江苏豪森药业股份有限公司 聚乙二醇修饰的胸腺肽1衍生物
US7740861B2 (en) 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US20060036080A1 (en) * 2004-07-16 2006-02-16 Bossard Mary J Conjugates of GM-CSF moiety and a polymer
CA2633435A1 (en) 2004-12-15 2006-06-22 Robert S. Hodges Antimicrobial peptides and methods of use
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
GB0501008D0 (en) * 2005-01-18 2005-02-23 Amura Therapeutics Ltd Method of producing conjugate vaccines
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Peg化された単鎖インスリン
EP2510942B1 (en) 2005-04-07 2015-09-02 Cardiorentis AG Use of natriuretic peptide for treating heart failure
EP1885403B1 (en) 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
ES2514470T3 (es) 2005-05-25 2014-10-28 Aerogen, Inc. Sistemas y métodos de vibración
PT2279758E (pt) * 2005-06-16 2015-05-27 Nektar Therapeutics Conjugados possuindo uma ligação degradável e reagentes poliméricos úteis na preparação de tais conjugados
AU2006289259A1 (en) 2005-09-08 2007-03-15 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
US20090035287A1 (en) * 2005-09-26 2009-02-05 Zurit Levine Atrial natriuretic peptide (anp) splice variants and methods of using same
CN100577685C (zh) 2005-11-10 2010-01-06 中国人民解放军军事医学科学院毒物药物研究所 长效胸腺素α1的聚乙二醇化修饰物
EP1797901A1 (en) 2005-12-16 2007-06-20 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
EP2364735A3 (en) * 2005-12-16 2012-04-11 Nektar Therapeutics Branched PEG conjugates of GLP-1
EP2001500A4 (en) 2006-03-10 2010-07-28 Dyax Corp FORMULATIONS FOR ECALLANTIDE
WO2007109564A2 (en) 2006-03-17 2007-09-27 University Of Massachusetts Yeast cell particles as oral delivery vehicles for antigens
EP2038424A2 (en) 2006-06-21 2009-03-25 Enzon Pharmaceuticals, Inc. Stabilized proteins
EP2044150B1 (en) * 2006-07-21 2014-01-15 Nektar Therapeutics Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
EP1900742A1 (en) * 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
NZ575804A (en) 2006-09-13 2012-01-12 Univ Columbia Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
JP2008156283A (ja) * 2006-12-25 2008-07-10 Kyowa Hakko Kogyo Co Ltd 水溶性ポリマー修飾ポリペプチドの製造方法
MX2009007145A (es) * 2006-12-27 2009-08-27 Nektar Therapeutics Al Corp Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
RU2007137048A (ru) 2007-10-05 2009-04-10 Общество С Ограниченной Ответственностью "Концерн О3" (Ru) Лекарственное средство для лечения и предупреждения осложнений при сахарном диабете
DK2209494T3 (en) 2007-10-09 2016-10-03 Polytherics Ltd New conjugated proteins and peptides
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
WO2010033205A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of v681-like peptides
EP2337585A1 (en) 2008-09-19 2011-06-29 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
EP2334337A1 (en) 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
US20110171162A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of thymosin alpha 1 peptides
WO2010033222A2 (en) 2008-09-19 2010-03-25 Netkar Therapeutics Polymer conjugates of ziconotide peptides
EP2340045B1 (en) 2008-09-19 2017-04-12 Nektar Therapeutics Polymer conjugates of protegrin peptides
US20110171166A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of osteocalcin peptides
US20110165112A1 (en) 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
US20110237524A1 (en) 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
WO2010033216A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of nesiritide peptides
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
EP2340048A1 (en) 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of biphalin peptides
EP2340047A1 (en) 2008-09-19 2011-07-06 Nektar Therapeutics Polymer conjugates of kiss1 peptides

Also Published As

Publication number Publication date
US20110166063A1 (en) 2011-07-07
US9682153B2 (en) 2017-06-20
EP2898900A1 (en) 2015-07-29
US20190070251A1 (en) 2019-03-07
US8680263B2 (en) 2014-03-25
CA2737040A1 (en) 2010-03-25
WO2010033240A3 (en) 2010-06-17
WO2010033207A1 (en) 2010-03-25
AU2009292643B2 (en) 2016-02-18
EP2350118A2 (en) 2011-08-03
US20160022828A1 (en) 2016-01-28
EP2350118B1 (en) 2016-03-30
EP2341942A1 (en) 2011-07-13
JP2015134832A (ja) 2015-07-27
EP2898900B1 (en) 2017-11-15
US9173951B2 (en) 2015-11-03
CA2737040C (en) 2017-05-02
WO2010033240A2 (en) 2010-03-25
US20150051371A1 (en) 2015-02-19
JP5765813B2 (ja) 2015-08-19
JP2012502990A (ja) 2012-02-02
US20110171716A1 (en) 2011-07-14
AU2009292643A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
AU2009292643B2 (en) Polymer conjugates of therapeutic peptides
US8449872B2 (en) Polymer conjugates of nesiritide peptides
JP2012116864A (ja) Glp−1化合物
EP2337585A1 (en) Polymer conjugates of glp-2-like peptides
US20120195847A1 (en) Polymer conjugates of biphalin peptides
US20080085860A1 (en) Selective Vpac2 Receptor Peptide Agonists
WO2010033224A1 (en) Polymer conjugates of kiss1 peptides
EP2334337A1 (en) Polymer conjugates of opioid growth factor peptides
US20060105948A1 (en) GLP-2 derivatives
US9763995B2 (en) Polymer conjugates of protegrin peptides
US20110165113A1 (en) Polymer conjugates of v681-like peptides
US20110237524A1 (en) Polymer conjugates of aod-like peptides
WO2010033227A1 (en) Polymer conjugates of thymosin alpha 1 peptides

Legal Events

Date Code Title Description
FG Grant or registration